Results were adjusted for age, race, comorbidity status, cancer stage, zip code income, zip code education, urban area, marital status, year of diagnosis, state buy-in status.
A, Prostate cancer-specific survival was similar in areas with high and low use of primary androgen deprivation therapy (ADT) (high use and low use, respectively) among men with moderately differentiated cancer and poorly differentiated cancer.
B, Overall survival was similar in highland low-use areas among men with moderately differentiated cancer and poorly differentiated cancer.